DLA PIPER LLP (US) lobbying for BIOTECHNOLOGY INNOVATION ORGANIZATION

Filing Registration

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jun 18, 2025

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 3

RICHARD BURR Former member of Congress New on this filing

Previously held: U.S. Senator
MARGARET MARTIN New on this filing

Previously held: Senior FDA Policy Advisor, Senate Health, Education, Labor and Pensions Committee; Health Policy Assistant, Sen. Richard Burr
VINCENT SARUBBI JR New on this filing

Previously held: Deputy Chief of Staff and Legislative Director, Rep. Josh Gottheimer; Legislative Assistant, Sen. Sherrod Brown; Senior Legislative Assistant, Rep. Donald Norcross; Legislative Assistant, Rep. Rob Andrews

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Lobbying activity 4

Pharmacy

Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.

Medical/Disease Research/Clinical Labs

Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.

Health Issues

Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.

Medicare/Medicaid

Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.